HSA
ASND icon

Hussman Strategic Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Hussman Strategic Advisors’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8,400
Closed -$1.92M – 242
2026
Q1 		$1.92M Buy
+8,400
New +$1.88M 0.42% 110

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Hussman Strategic Advisors's ASND Position: Q2 2026 in Review

Hussman Strategic Advisors sold out of Ascendis Pharma A/S (ASND) in Q2 2026, closing a stake of 8,400 shares — an estimated $1.92M sold.

Hussman Strategic Advisors first reported a position in ASND in Q1 2026 and held it in 1 quarter. The position peaked at $1.92M in Q1 2026. 313 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

  • Hussman Strategic Advisors reported no remaining Ascendis Pharma A/S position as of Q2 2026 after selling out during the quarter.
  • Hussman Strategic Advisors sold 8,400 Ascendis Pharma A/S shares in Q2 2026, an estimated $1.92M.
  • Hussman Strategic Advisors first reported a position in Ascendis Pharma A/S in Q1 2026 and held it in 1 quarter.
  • Hussman Strategic Advisors's Ascendis Pharma A/S position peaked at $1.92M in Q1 2026.
  • 313 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Hussman Strategic Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.